https://doi.org/10.1186/s13054-022-04145-3

(2022) 26:275

Busch et al. Critical Care

Open Access



Markus Busch^{1*}, Marius M. Hoeper^{2,3}, Constantin von Kaisenberg⁴, Thomas Stueber⁵ and Klaus Stahl¹

Dear Editor,

The SARS-CoV-2 pandemic resulted in an unprecedented number of severe cases among pregnant women [1, 2]. To date, there have been only few reports of the specific issues that arise during the intensive care treatment of pregnant women with lung failure due to Covid-19 [3, 4]. Complex medical decision-making is required in the management of critically ill pregnant women [5] and further data is needed to guide prognostication of outcomes and clinical decision making.

We here present a case series of 14 pregnant and peripartum women with severe acute respiratory distress syndrome (ARDS) due to Covid-19 treated at our institution between January 2020 and December 2021.

Figure 1 summarizes the different ICU courses; Table 1 displays the maternal characteristics. Figure 2 displays the individual ICU course of included patients. The median maternal age was 31 years (Interquartile Range (IQR) 28–37) and the median gestational age on ICU admission 26 weeks (22–32). The median ICU length of stay was 14 days (6–34) days, 13/14 (92.8%) women had severe and 1/14 (12.5%) had moderate ARDS, the median PaO₂/FiO₂ (PF ratio) on admission was 74 mmHg (60–93).

10/14 (71.4%) women required invasive mechanical ventilation, 6/14 (42.8%) with additional extracorporeal membrane oxygenation (ECMO). 4/14 (28.5%) patients could be managed with non-invasive support, 3/14 (21.4%) with high flow nasal cannula (HFNC) and 1/14 (7.1%) with non-invasive ventilation (NIV). Prone positioning was used in 5/14 (35.7%) patients. Specific Covid-19 therapies included Remdesivir in 3/14 (21.4%), Tocilizumab in 5/14 (35.7%) and Glucocorticoids in 12/14 (85.7%).

7/14 (50%) women had isolated ARDS in pregnancy and another 7/14 (50%) had multi organ failure (MOF), defined by additional non-pulmonary organ specific sub-SOFA scores \geq 2 points. In 3/14 (21.4%) MOF developed after delivery of women with previously isolated ARDS.

Considering all MOF together, the second most common organ failure besides ARDS was circulatory failure in 10/14 (71%) women. Kidney failure was present in 5/14 (36%) women. In 4/14 (29%) there was maternal cardiac failure, 3/14 (21.4%) with predominant left heart and one right heart failure, and 2/14 (14.2%) required additional arterial ECMO cannulation for circulatory support.


None of the 7/14 (50%) patients with isolated ARDS during pregnancy died. In 3/14 (21.4%) women, caesarean section was performed while on the ICU between gestational weeks 33 and 38 due to progressive respiratory failure. These women and their offspring survived but all 3 women developed MOF after delivery. All maternal and fetal deaths occurred in patients with MOF who required high-dose catecholamine support: 2/14 (14.2%) of the women and 4/14 (28.5%) of the unborn died. Two intrauterine fetal deaths (IUFD) occurred in the setting of maternal MOF at 21 and 28 weeks' gestation, respectively. One stillbirth occurred at gestational week 17 after maternal recovery from MOF, and one patient requested



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: busch.markus@mh-hannover.de

¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany Full list of author information is available at the end of the article



abortion at 30 weeks' gestation after she had already left ICU because her child displayed severe ischemic brain damage presumably resulting from maternal MOF and profound shock.

All 7/14 (50%) women with MOF were before 28 weeks' gestation, 3/14 (21.4%) were before gestational week 24, before viability, thus delivery was not a reasonable option. The other 4/14 (28.5%) patients with MOF were between gestational week 26 and 28. In these patients, emergency caesarean section was discussed on a daily basis within a multidisciplinary team consisting of critical care and obstetric professionals.

In summary, the management of pregnant patients with severe Covid 19 is complex and requires a multidisciplinary approach. Despite the relatively small sample size, our data suggest that patients with severe Covid-19-related ARDS can be successfully carried through pregnancy with invasive ventilation and ECMO, if needed, as long as they suffer from isolated lung failure. However, the risk of maternal and fetal death increases substantially once MOF develops. Additional circulatory failure requiring high-dose catecholamine support seems to be the major determinant of adverse maternal and fetal outcome in pregnant women with severe Covid-19 associated ARDS.


The decision regarding delivery in women with severe Covid-19 associated ARDS needs to balance multiple risks and benefits, including the risk of prematurity to the fetus, the potential to improve or worsen maternal respiratory status with delivery, and the risks accompanying major surgery such as cesarean section, particularly in patients requiring ECMO support. These preliminary

cteristics
Jara
tient c
e 1 Pa
Tablo

-	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13	Patient 14
Maternal factors	2													
Age (years)	37	34	38	27	29	30	39	28	32	26	38	28	34	21
Weight (kg) 9	06	97	70	124	85	87	103	60	06	130	75	72	70	60
BMI	29	34	27	4	32	33	39	23	35	42	27	29	26	22
Gravida/Para (G6/P5	G4/P3	G4/P3	G1/P0	G2/P1	G1/P0	G2/P1	G1/P0	G5/P4	G4/P1	G8/P3	G1/P0	G3/P2	G2/P1
Gestational 3 age (admis- sion ICU)	26	34	22	28	80	33	22	28	24	19	21	31	17	26
Comorbidi- E ties	Eclampsia	HIV, hepatitis B	S	Obesitas	Asthma	Thalassemia	Obesitas			Arte- rial hyper- tension	Diabetes, arterial hyperten- sion		Pyelone- phritis	
Days on ICU 16 Maternal Covid-19	16 1-19	64	52	0	33	38	2	L.	10	2	11	Q	23	21
Symptom onset (days)	00	Q	4	00	6	7	Ŋ	10	6	n.a	00	10	7	n.a
	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR	PCR
CRP (mg/l)	172	115	135	88	119	60	31	138	109	75	174	60	65	184
PCT (mcg/l) (0.2	0.2	0.2	0.2	0.6	0.7	0.2	0.3	0.1	0.1	0.5	0.8	0.8	9.0
White-cell 2 count (× 10 ⁻³ / mm ³)	21.7	9.2	7.8	7.2	10.7	13.1	7.2	11.8	7.2	7.5	11.8	9.8	7.3	14.2
7 (I/N) HOT	435	299	379	569	425	464	195	408	393	364	351	310	462	432
Troponin (ng/l)	29	9	< 3.3	n.a	4	5	4	4	6	n.a	10	4	< 3.3	5
Ferritin (mcg/l)	193	76	94	337	179	201	43	66	151	221	171	105	749	290
D-Dimer (mg/l)	3.33	2.01	1.23	2.26	1.69	2.63	1.58	2.5	0.59	0.69	1.81	6.39	0.82	1.02
Fibrinogen ((g/l)	6.98	5.82	6.5	6.1	n.a	3.9	n.a	n.a	5.79	6.13	n.a	3.73	n.a	n.a
Invasive ventilation	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	No	Yes	No	Yes	Yes
PEEP/pla- teau (cm/ H ₂ O)	16/32	10/26	12/27	15/13	15/16	15/15	n.a	n.a	16/18	n.a	16/15	n.a	12/16	14/16
Horowitz/PF	78	61	62	48	56	70	96	95	112	78		67	84	67

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12	Patient 13	Patient 14
Prone position- ing during pregnancy	° Z	0 N	Yes	Yes	°Z	°Z	0 Z	°Z	Yes	N	Yes	°Z	Yes	Q
ECMO	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No
Covid-19 targeted therapy	Remdesivir No	No	Tocilizumab	No	Tocilizumab	Tocilizumab	N	No	No	Tocilizumab	N	Remdesivir	Remdesivir	Tocilizumab
Systemic steroids	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Vasoactives	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	No	Yes	No	Yes	Yes
AKI	Yes	Yes	No	Yes	Yes	No	No	No	No	No	Yes	No	No	No
Dialysis	Yes	No	No	Yes	Yes	No	No	No	No	No	Yes	No	No	No
Heart failure	No	Yes	No	Yes	Yes	No	No	No	No	No	Yes	No	No	No
SOFA score ad admis- sion	6	m	2	5	2	2	5	2	~	2J	ω	2	e	ſ
Maternal survival to hospital discharge	Yes	Yes	Yes	ON	Yes	Yes	Yes	Yes	Yes	Yes	ON	Yes	Yes	Yes
Unborn/ newborn survival to hospital discharge	0 N	Yes	Yes	0 Z	Yes	Yes	Yes	Yes	Yes	Yes	0 Z	Yes	0 N	Yes
Abortion/ stillborn	Yes	No	No	Yes	No	No	No	No	No	No	Yes	No	Yes	No
Delivery dur- No ing ICU	No	C-section	C-section	C-section	C-section	C-section	No	No	No	No	Transvaginal	No	Transvaginal	No
Displayed are <i>BMI</i> body mas: membrane oxy	both demogral s index, G gravi ygenation, AKI	phic and clinica ida, <i>P</i> para, <i>ICU</i> i acute kidney in	Displayed are both demographic and clinical patient characteristics BMI body mass index, G gravida, P para, ICU intensive care unit, CRP membrane oxygenation, AKI acute kidney injury, SOFA sequential or	eristics of ind iit, <i>CRP</i> c-react ntial organ fa	ividual patient: tive protein, <i>PC</i> ilure assessmer	. Laboratory val T procalcitonin, nt, MOF multior <u>c</u>	lues and num LDH lactate (3an failure, A.	herical indices dehydrogena: <i>RDS</i> adult resj	s of disease se se, <i>PEEP</i> posit piratory distru	everity were rec tive endexpirato ess syndrome, (of individual patients. Laboratory values and numerical indices of disease severity were recorded at critical care admission c-reactive protein, <i>PCT</i> procalcitonin, <i>LDH</i> lactate dehydrogenase, <i>PEEP</i> positive endexpiratory pressure, <i>PF ratio</i> PaO ₂ /FiO ₂ gan failure assessment, <i>MOF</i> multiorgan failure, <i>APDS</i> adult respiratory distress syndrome, C-section cesarean section	care admissior atio PaO ₂ /FiO ₂ n section	of individual patients. Laboratory values and numerical indices of disease severity were recorded at critical care admission c-reactive protein, <i>PCT</i> procalcitonin, <i>LDH</i> lactate dehydrogenase, <i>PEEP</i> positive endexpiratory pressure, <i>PF ratio</i> PaO ₂ /FiO ₂ ratio, <i>ECM</i> O extracorporeal gan failure assessment, <i>MOF</i> multiorgan failure, <i>ARD</i> S adult respiratory distress syndrome, <i>C-section</i> cesarean section	acorporeal

Table 1 (continued)



volume challenge as circulatory failure. We distinguished high dose (> 0.1 mcg/kg/min) from low dose catecholamines (< 0.1 mcg/kg/min). Acute kidney injury (AKI) was diagnosed according to the Acute Kidney Injury Network (AKIN) classification. An isolated and marginally elevated bilirubin was not assessed as sign of liver failure and low platelets under ECMO-therapy were not considered to be organ failure, since both had likely other confounders. *HFNC* high flow nasal canula, *NIV* noninvasive ventilation, *ITN* intubation, *ARDS* adult respiratory distress syndrome, *ECMO* extracorporeal membrane oxygenation, *H* high dose catecholamines

observations need to be tested in larger multicenter studies.

Author contributions

MB collected the data and wrote the original draft. MMH, CK, TS and KS reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany. ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany. ³German Centre for Lung Research, Hannover, Germany. ⁴Department of Obstetrics, Gynecology and Reproductive Medicine, Hannover Medical School, Hannover, Germany. ⁵Department of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany.

Received: 25 July 2022 Accepted: 29 July 2022 Published online: 13 September 2022

References

- Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Azria E, Blanc J, Bohec C, Bornes M, Ceccaldi PF, Chalet Y, Chauleur C, Cordier AG, Desbriere R, Doret M, Dreyfus M, Driessen M, Fermaut M, Gallot D, Garabedian C, Huissoud C, Luton D, Morel O, Perrotin F, Picone O, Rozenberg P, Sentilhes L, Sroussi J, Vayssiere C, Verspyck E, Vivanti AJ, Winer N, Alessandrini V, Schmitz T. A snapshot of the Covid-19 pandemic among pregnant women in France. J Gynecol Obstet Hum Reprod. 2020;49(7):101826. https://doi.org/10.1016/j.jogoh.2020.101826.
- (CDC) CfDCaP. Data on COVID-19 during pregnancy. 2022. https://www. cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/ pregnancy-data-on-covid-19.html.
- 3. Schnettler WT, Al Ahwel Y, Suhag A. Severe acute respiratory distress syndrome in coronavirus disease 2019-infected pregnancy: obstetric and

intensive care considerations. Am J Obstet Gynecol. 2020;2(3):100120. https://doi.org/10.1016/j.ajogmf.2020.100120.

- Morau E, Bouvet L, Keita H, Vial F, Bonnet MP, Bonnin M, Le Gouez A, Chassard D, Mercier FJ, Benhamou D, Obstetric A, Critical Care Club Working G. Anaesthesia and intensive care in obstetrics during the COVID-19 pandemic. Anaesth Crit Care Pain Med. 2020;39(3):345–9. https://doi.org/ 10.1016/j.accpm.2020.05.006.
- Zieleskiewicz L, Chantry A, Duclos G, Bourgoin A, Mignon A, Deneux-Tharaux C, Leone M. Intensive care and pregnancy: Epidemiology and general principles of management of obstetrics ICU patients during pregnancy. Anaesth Crit Care Pain Med. 2016;35(Suppl 1):S51–7. https:// doi.org/10.1016/j.accpm.2016.06.005.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

